Ketorolaco Trometamol Normon

Ketorolac Trometamol, the active ingredient in Ketorolaco Trometamol Normon, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an injectable solution for intramuscular and intravenous use. It is employed for short‑term management of moderate to severe pain in adult patients. GNH USA supplies Ketorolaco Trometamol Normon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ketorolac Trometamol is an NSAID indicated for acute pain conditions where rapid analgesia is required. - Post‑operative pain: provides effective analgesia for up to 24 hours after surgery. - Acute musculoskeletal pain: reduces pain intensity following injury or strain. - Renal colic: offers short‑term relief of severe flank pain associated with kidney stones.

Adverse reactions may occur with ketorolac use.

Common Side Effects: - Nausea or vomiting - Headache - Dizziness or vertigo - Injection‑site pain or erythema - Gastro‑intestinal discomfort - Elevated blood pressure

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding - Acute renal impairment or failure - Severe hypersensitivity reactions (e.g., anaphylaxis) - Cardiovascular thrombotic events (myocardial infarction, stroke) - Hepatic enzyme elevation or liver injury - Hematologic abnormalities such as thrombocytopenia

Ketorolac should be used with careful clinical assessment and monitoring. - Assess renal function: avoid in patients with severe renal impairment. - Monitor gastrointestinal risk: use the lowest effective dose for the shortest duration. - Check bleeding risk: contraindicated in active bleeding or coagulopathy. - Avoid in patients with known hypersensitivity to NSAIDs or aspirin. - Use with caution in cardiovascular disease: monitor blood pressure and signs of ischemia. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Ketorolac may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of serious bleeding. - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity. - Selective serotonin reuptake inhibitors (SSRIs): heightened bleeding tendency.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may reduce renal perfusion, especially in volume‑depleted patients. - Diuretics: combined use can precipitate renal impairment. - Lithium: NSAIDs may increase serum lithium concentrations, requiring level monitoring.